In this interview from the Oncology Nursing Society (ONS) 2023 Congress, Oncology Data Advisor speaks with Lauren Ghazal, PhD, FNP-BC, a Family Nurse Practitioner and Post-Doctoral Research Fellow at the University of Michigan. Dr. Ghazal was honored at ONS Congress as a recipient of the 2023 Mara Mogensen Flaherty Memorial Lectureship Award to discuss "Current Challenges: Nursing Sustainability" along with fellow recipients Suzanne Carroll, RN, MS, AOCN®; Amy E. Rettig, DNP, MALM, MSN, BSN, RN ACNS-BC, PMHNP-BC; and 2000 Mara Mogensen Flaherty Memorial Lectureship Award recipient Debi Boyle, MSN, RN, AOCNS®,FAAN, serving as moderator. In this interview, Dr. Ghazal highlights her inspiring work and research investigating nursing sustainability and cancer survivorship for adolescents and young adults, and shares how to encourage more individuals to pursue a fulfilling career in nursing and research.
At the recent American Society of Clinical Oncology (ASCO) Annual Meeting, Ian Krop, Director of the Yale Cancer Center Clinical Trials Office, sat down with Oncology Data Advisor to discuss his research and the data he presented regarding the HER3-targeting antibody-drug conjugate patritumab deruxtecan (HER3-DXd) for treatment of metastatic breast cancer.
This podcast episode was recorded live at the 2022 ASCO Annual Meeting in Chicago by Oncology Data Advisor and ConveyMED.
At the recent American Society of Clinical Oncology (ASCO) Annual Meeting, Dr. Wendy London, Associate Professor of Pediatrics at Harvard Medical School, sat down with Oncology Data Advisor to share her research regarding risk stratification, reduction of therapy, and survival outcomes for pediatric patients with neuroblastoma.
This podcast episode was recorded live at the 2022 ASCO Annual Meeting in Chicago by Oncology Data Advisor and ConveyMed.
At the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Dr. Jeanne Tie spoke with Oncology Data Advisor to share more about her presentation regarding the clinical utility of circulating tumor DNA (ctDNA) analysis to guide treatment decision making for patients with colorectal cancer.
At the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Ms. Stephanie Van Winkle, Executive Director of the Oncology State Societies at the Association for Community Cancer Centers (ACCC), sat down with Oncology Data Advisor to discuss how the oncology state societies and the Association for Community Cancer Centers empower legislative advocacy work.
This podcast episode was recorded live at the 2022 ASCO Annual Meeting in Chicago by Oncology Data Advisor and ConveyMed.
At the recent Oncology Nursing Society (ONS) Congress in Anaheim, California, Charles B. Simone, II, MD, FACRO, explained the concepts underlying the treatment of cancer with radiation therapy. In this interview with Oncology Data Advisor, Dr. Simone discusses the different types of radiation treatments and some considerations in choosing treatment. He also shares current evidence from his research about synergy between radiation therapy and checkpoint inhibitors or chemotherapy.
At the recent Oncology Nursing Society (ONS) Congress in Anaheim, California, Bina Parekh, PhD, explained the concept of vicarious trauma and empowered nurses with positive personal growth strategies to deal with challenges, fears, and trauma that stem from dealing with patients with cancer. In this interview with Oncology Data Advisor, Dr. Parekh discusses the concept of vicarious trauma and how nurses, programmed to care for others, are often affected. She shares advice for nurses on how to ad...
In the phase 3 BELINDA trial, a team of researchers led by Dr. Michael Bishop, Director of Hematopoietic Stem Cell Transplantation at the University of Chicago Medicine, investigated tisagenlecleucel (tisa-cel), a chimeric antigen receptor (CAR) T-cell therapy, as second-line treatment for patients with relapsed/refractory aggressive non-Hodgkin lymphoma. The investigators found that tisa-cel did not improve event-free survival compared with the standard of care, which consisted of platinum-based chemotherapy followed by autologous stem cell transplant in responders. Dr. Bishop recently presented the results of the trial at the 63rd American Society of Hematology (ASH) Annual Meeting & Exposition in Atlanta, Georgia. In this interview with Oncology Data Advisor, he explains how these results should be interpreted and their significance for the future of CAR T-cell therapy.
The outcomes of patients with lung cancer have improved significantly in recent years, largely due to the treatment targeting the cancer's specific genetic profile and the impact of immunotherapy, often in different groups of patients. In this interview, Ross Camidge, MD, PhD, Director of Thoracic Oncology at the University of Colorado Cancer Center, discusses the importance of considering multiple factors when deciding on clinical trials for patients. Oncology Data Advisor: When would you recom...
To celebrate Breast Cancer Awareness Month, Kathy Pratt, BSN, RN, OCN®, CBCN®, ONN-CG, a genetic patient navigator at UT Southwestern Simmons Comprehensive Cancer Center, discusses her role in reaching out to patients identified to have a greatly increased risk of developing cancer in their lifetimes. In this interview, she shares her advice in helping individuals prevent cancer, as well as her answers to her patients' common questions about breast cancer.
An educational activity designed by i3 Health has demonstrated significant learning gains in the treatment and management of myelodysplastic syndromes (MDS) and has been presented at the 2021 Greater Los Angeles Oncology Nursing Society (GLAONS) Oncology Care Summit. A group of myeloid clonal hematopoietic disorders with a relatively heterogeneous spectrum of presentation, MDS, is associated with clinical problems resulting from cytopenias, which can evolve into acute myeloid leukemia. The incid...
In the following interview, Dr. Paul Richardson, the Clinical Program Leader and Director of Clinical Research of the Jerome Lipper Multiple Myeloma Center at the Dana-Farber Cancer Institute, discusses some important factors in the development of drugs to target "the queen of immunological cancers," multiple myeloma, and why this disease is difficult to cure. Recently, he led the development and clinical trials of the novel targeted cytotoxic peptide-drug, melphalan flufenamide (Pepaxto®, Oncop...
Follicular lymphoma, an indolent, difficult-to-treat B-cell malignancy, is complicated by evolving disease subtypes. Patient outcomes can be hampered by the failure of the multidisciplinary team to establish consensus on the optimal timing, schedule, and length of follicular lymphoma treatment. In addition, the rapid pace of research makes it difficult to stay abreast of the latest and most clinically relevant therapies. This educational gap in the treatment and management of follicular lymphoma...
Melphalan flufenamide, a newly approved peptide-drug conjugate for multiple myeloma, specifically targets chemotherapy to tumor cells like a warhead on a guided missile. In the following interview, Dr. Paul Richardson, the Clinical Program Leader and Director of Clinical Research of the Jerome Lipper Multiple Myeloma Center at the Dana-Farber Cancer Institute, discusses the use of melflufen (Pepaxto®, Oncopeptides AB) for multiple myeloma. Melflufen has its base in melphalan and the old technolo...
A shortfall in knowledge in the use of biomarkers and patient-related factors for the personalization of treatment for patients with advanced urothelial carcinoma was identified in the baseline data collected from i3 Health's continuing medical education (CME)–approved visiting faculty meeting series titled New Thinking, New Strategies in Advanced Urothelial Carcinoma, led by Arjun V. Balar, MD, Associate Professor of Medicine and Director of the Genitourinary Medical Oncology Program at NYU Lan...
Recently, the FDA granted approval to lorlatinib (Lorbrena®, Pfizer, Inc.) for the treatment of patients with anaplastic lymphoma kinase (ALK)–positive non-small cell lung cancer. This subset of lung cancers defined by their chromosomal rearrangements of the ALK gene are highly sensitive to small-molecule ALK tyrosine kinase inhibitors (TKIs). Lorlatinib is a novel third-generation small-molecule ALK TKI that was designed to cross the blood-brain barrier in an effort to better treat patients who...
When patients with hematological malignancies do not receive referrals for hematopoietic stem cell transplant (HSCT), they may face a risk of poorer outcomes. Common reasons behind this lack of referrals include provider confusion over eligibility criteria for HSCT, overestimation of the risks associated with transplant, and confusion regarding the benefit of HSCT. This educational gap regarding the uses and risks of HSCT was identified in the baseline data collected from i3 Health's continuing ...
The FDA has approved yttrium-90 (Y-90) glass microspheres (TheraSphere™, Boston Scientific) for the treatment of patients with unresectable hepatocellular carcinoma (HCC). The most common type of primary liver cancer, HCC is often treated with surgery, liver transplantation, chemotherapy, or embolization. The radioactive Y-90 glass microspheres are delivered directly to the liver tumor through a catheter. The treatment, referred to as selective internal radiation therapy or embolization, minimiz...
Multiple myeloma is a cancer of the bone marrow plasma cells that causes the overproduction of monoclonal immunoglobulins, which can lead to organ damage. In this excerpt of the transcript from her nursing continuing professional development (NCPD)-approved activity, Multiple Myeloma: Enhancing Treatment Tolerability, Adherence, and Patient-Centered Care, Beth Faiman, PhD, MSN, APN-BC, AOCN®, FAAN, a nurse practitioner at the Cleveland Clinic Taussig Cancer Institute, discusses strateg...
Prostate cancer is the tumor type with highest incidence in men in the United States. Typically, the first line treatment for progressive disease is androgen deprivation therapy (ADT). However, most men eventually stop responding to ADT treatment and develop castration-resistant prostate cancer (CRPC). The therapeutic options for this highly heterogeneous disease process have expanded to include novel hormone therapies, second-generation taxanes, immunotherapy, and bone-targeted and bone metasta...